Evommune, Inc. (EVMN)
12.48
-0.18
(-1.42%)
USD |
NYSE |
Sep 01, 16:00
12.48
0.00 (0.00%)
After-Hours: 18:59
Evommune Total Long Term Debt (Quarterly) : 7.392M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.392M |
| March 31, 2026 | 7.861M |
| December 31, 2025 | 1.818M |
| September 30, 2025 | 257.61M |
| June 30, 2025 | 257.74M |
| Date | Value |
|---|---|
| March 31, 2025 | 192.67M |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | 0.755M |
| Mineralys Therapeutics, Inc. | 97.62M |
| Arrowhead Pharmaceuticals, Inc. | 1.371B |
| Oncolytics Biotech, Inc. | 0.31M |
| Sangamo Therapeutics, Inc. | 19.33M |